24/7 Market News Snapshot 28 July, 2025 – CervoMed Inc. Common Stock (NASDAQ:CRVO)

July 28, 2025

DENVER, Colo., 28 July, 2025 (www.247marketnews.com) – (NASDAQ:CRVO) are discussed in this article.
CervoMed Inc. (CRVO) is witnessing a remarkable surge in its stock price, currently trading at $15.10, which reflects an impressive 68.11% increase from its prior close of $8.98 during the pre-market session. This notable bullish breakout is accompanied by robust trading activity, with 1.58 million shares exchanged, indicative of strong investor enthusiasm. The significant spike in shares may signal a positive shift in market momentum, potentially driven by recent developments within the company that warrant close attention from investors.

Crucially, CervoMed recently announced encouraging results from the 32-week Extension phase of its Phase 2b RewinD-LB trial. This study evaluated its investigational oral treatment, neflamapimod, aimed at addressing Dementia with Lewy Bodies (DLB). Unveiled at the Alzheimer’s Association International Congress, the findings revealed a substantial 54% reduction in the risk of clinically significant cognitive decline, as assessed by the Clinical Dementia Rating Sum of Boxes (CDR-SB) at the 32-week interval. The results are especially promising for patients with minimal Alzheimer’s co-pathology, showcasing a remarkable 64% risk reduction in this subgroup.

John Alam, MD, Co-Principal Investigator of the RewinD-LB trial and CEO of CervoMed, expressed optimism about the implications of these results, emphasizing the potential of neflamapimod to significantly impact disease progression. He stated that the data lays a strong foundation for advancing into a Phase 3 trial. Additionally, reductions in plasma levels of glial fibrillary acidic protein (GFAP), a marker linked to neurodegeneration, further reinforce the drug’s therapeutic promise.

As CervoMed anticipates discussions with regulatory authorities later this year, these groundbreaking results mark a vital step forward in addressing the needs of DLB patients, a group that currently lacks sufficient treatment options. The company’s dedication to developing effective therapies for neurodegenerative disorders remains a central focus, providing renewed hope for patients and families affected by these challenging conditions.

Related news for (CRVO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.